arrow
Y

Yoshiyuki Yamamoto

faculty of medicine
H指数:24
被引数:3,423

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G

晚期胃癌伴严重腹膜转移患者mFOLFOX6方案的II期研究(WJOG10517G),包括与JCOG1108/WJOG7312G的个体患者数据比较

2026-08-270
OAAI
Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: a secondary analysis of a randomized clinical trial

纳多美定在癌症疼痛患者初次使用阿片类药物时的新的止吐效果:一项随机临床试验的二次分析

2026-04-010
PRE
Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancer

局部晚期胰腺癌经大剂量质子束治疗后切除的安全性和病理影响

2025-10-020
OAAI
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

FOLFOX治疗晚期食管鳞癌的疗效和安全性

2025-03-070
OAAI
GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment

GDF15前肽通过增强骨微环境促进去势抵抗性前列腺癌骨转移

2024-11-250
OAAI
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC

Quattro-ii随机试验: CAPOXIRI bevacizumab与FOLFOXIRI bevacizumab作为mCRC患者的一线治疗

MED
IF11.8
2024-09-010
OA
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer

循环肿瘤DNA中BRCA和ATM突变状态在晚期胰腺癌治疗选择中的临床应用

2024-08-280
PRE
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
2024-03-010
OAAI
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy
2024-02-141
PRE
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

在TRUSTY研究中使用血浆血管生成相关因子和无细胞DNA进行探索性生物标志物分析: 一项关于三氟尿苷/替匹拉西加贝伐单抗作为转移性结直肠癌二线治疗的随机II/III期研究

2024-01-094
OAAI